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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Patients with chromosomal translocation are highly vulnerable to pro-
duce unbalanced gametes that result in recurrent miscarriages, affected offspring, or infer-
tility. Preimplantation genetic diagnosis (PGD) with blastomere biopsy and fluorescent
in-situ hybridization (FISH) has been used to select normal/balanced embryos for transfer.
However, FISH is inherent with some technical difficulties such as cell fixation and signal
reading. Here we introduce a strategy of PGD using blastocyst biopsy and array comparative
genomic hybridization (aCGH) for reproductive problems of patients with chromosomal trans-
location.
Methods: Twelve patients diagnosed as having chromosomal translocation who underwent PGD
cycles were included in this single-center observational study. Blastocyst biopsy was per-
formed and biopsied blastocysts were cryopreserved individually. Testing was performed with
aCGH, and the euploid embryos were transferred in the following thawing cycles.nt of Obstetrics and Gynecology, National Taiwan University Hospital, 7 Chung-Shan South Road,
.tw (H.-F. Chen), sheeuan@ntu.edu.tw (S.-U. Chen).
to this study.
ight ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
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538 C.-C. Huang et al.Results: The overall diagnostic efficiency was 90.2% (55/61) and the euploidy rate was 32.7%
(18/55). Ten cycles of thawed embryo transfer (ET) were carried out, resulting in three live
births and another three ongoing pregnancies with an ongoing pregnancy rate of 60%/transfer
cycle. The prenatal diagnosis with chorionic villi sampling confirmed the results of PGD/aCGH
in all six pregnant women. No miscarriage happened in our case series.
Conclusion: Our study demonstrates an effective PGD strategy with promising outcomes. Blas-
tocyst biopsy can retrieve more genetic material and may provide more reliable results, and
aCGH offers not only detection of chromosomal translocation but also more comprehensive
analysis of 24 chromosomes than traditional FISH. More cases are needed to verify our results
and this strategy might be considered in general clinical practice.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Chromosomal rearrangements are the most common struc-
tural chromosome abnormalities, with an estimated 0.19%
prevalence in the general population, and even higher in
certain populations, such as 5% in patients who underwent
in vitro fertilization (IVF) treatments and experienced
recurrent miscarriages and repeated IVF failure.1 Carriers of
balanced chromosomal rearrangements usually have normal
phenotype, but have a high risk (19e77%) of producing
chromosomally unbalanced gametes following abnormal
meiotic segregation, depending on the type of chromosome
aberration, the chromosomes involved, and the number and
location of breakpoints.2 This may result in infertility,
recurrent miscarriages (spontaneous or induced after pre-
natal diagnosis), or delivery of an affected offspring with
mental retardation or other congenital abnormalities.1,3
In the past, these patients could only have prenatal
diagnosis to confirm the karyotype of the fetus after
considerable time and effort to get pregnant, and they may
even suffer more if the results show an unbalanced trans-
location. Alternatively, they might decide to choose a
sperm donor or oocyte donor after repeated failure to
achieve a normal pregnancy. Sometimes this may cause
infertility and usually the couples experience repeated IVF
failures and enormous psychological stress when they seek
help from assisted reproductive technologies (ART).3,4
Preimplantation genetic diagnosis (PGD), combined with
ART, can identify and select only chromosomally normal or
balanced embryos to be transferred to the uterus.5e7 It has
been shown that PGD can significantly shorten the time to
achieve a successful live birth from 4e6 years to<4 months,
and decrease the incidence of miscarriage from >90% to
<15% in the translocation carriers.4,8 This offers an alter-
native for the carriers in that they do not need to suffer from
the tremendous grief of repeated early pregnancy losses or
to terminate the affected pregnancy once revealed by the
prenatal diagnosis.4
The most widespread method of PGD for translocation is
eight-cell stage embryo biopsy with fluorescence in situ hy-
bridization (FISH) followed by Day 4 or Day 5 embryo transfer
(ET) in a fresh IVF cycle.9e11 However, the FISH method has
some drawbacks including difficulties in fixation of blasto-
meres, hybridization failure, signal overlap, and signal split-
ting that can affect the accuracy of the interpretation.12,13
Newer techniques have been proposed to increase thediagnostic accuracy and efficiency, such as the application of
polymerase chain reaction (PCR)-based PGD protocol, meta-
phase comparative genomic hybridization (CGH), and array
CGH (aCGH).1,3 However, FISH and PCR-based methods only
allow identification for a limited number of chromosomes,
whereas CGH and aCGH can detect all 24 chromosomes.
Although FISH methods are cheaper and can usually provide
translocation screening, they usually need workup to deter-
mine the appropriate probes to be utilized for the often de-
novo rearrangements specific to the individual. Also, they
do not allow for comprehensive aneuploidy screening.1,3,12
Furthermore, in some cases commercial FISH probes are not
available for the chromosome of interest due to cross hy-
bridization with other regions. However, these patients can
now benefit from aCGH as it is genome wide and does not
require a specific test to be developed.1,3,11,12
The most suitable methodological design in the practice
of PGD has not been well established. Polar body biopsy can
be used for the genetic analysis of the oocyte but is not
feasible for detecting male genetic problems. In contrast to
eight-cell embryo biopsy, blastocyst biopsy provides more
cells than the cleavage-stage biopsy (5e10 cells vs. 1 or 2
cells) for genetic analysis and may potentially increase the
diagnostic accuracy. Both of them allow analysis of chro-
mosomes from maternal and paternal origin.6,7,14 Here we
report a strategy of PGD using blastocyst biopsy, aCGH, and
thawed ET for patients with chromosomal translocation.
We analyzed the data of clinical treatments. The pre-
liminary results indicate that this strategy is an important
option for these patients.Materials and methods
Study population
This was a single-center observational study. Patients who
were diagnosed as having chromosomal translocations and
requested PGD at National Taiwan University Hospital from
January 2011 to April 2012 were included. A comprehensive
counseling was provided by an experienced clinical genet-
icist and reproductive endocrinologist to each couple prior
to starting the treatment. The participants were well
informed on the procedures of IVF and PGD with aCGH, its
efficacy, and limitations. Data on the parental age, family
and reproductive history, reasons for karyotyping, and their
PGD with aCGH for chromosomal rearrangement 539specific types of chromosomal aberration were recorded.
Written informed consent was obtained from each couple.
This study was approved by the Ethics Committee of Na-
tional Taiwan University Hospital.
For each PGD cycle the following data were recorded:
the number of retrieved oocytes; number of mature oo-
cytes (metaphase II oocytes); number of fertilized oocytes;
number of biopsied embryos; location and size of chromo-
somal aberrations in each diagnosed embryos; and preg-
nancy outcomes after ET. The primary outcome
measurements were diagnostic rate, euploidy rate, and
ongoing pregnancy rate.
Blastocyst biopsy and cryopreservation of biopsied
embryos
Ovarian stimulation was performed with either
gonadotropin-releasing hormone (GnRH) antagonist proto-
col or GnRH agonist short protocol as described pre-
viously.15e17 Retrieval of oocytes was performed vaginally.
In order to avoid contamination from sperm or surrounding
cumulus cells, intracytoplasmic sperm injection was per-
formed in every case. Embryos that had reached blastocyst
stage were biopsied at trophectoderm on either Day 5 or
Day 6, based on the method described by Chen et al.18 Five
to 10 trophoblasts were aspirated from each blastocyst and
were transferred to a separate PCR tube. The biopsied
blastocyst was treated with cryoprotectants and trans-
ferred onto a Cryotop (Kitazato Supply Co., Fujinomiya,
Japan) individually.19
Whole genome amplification and aCGH
The multiple displacement amplification method using
SurePlex Whole Genome Amplification (WGA) Kit (Blue-
Gnome, Cambridge, UK) was performed for WGA, according
to the manufacturer’s instruction. This technology is based
on random fragmentation of genomic DNA and subsequent
amplification by PCR utilizing flanking universal priming
sites. Amplified sample DNA and control DNA were then
labeled with Cy3 and Cy5 fluorophores respectively and co-
hybridized competitively to a bacterial artificial chromo-
some microarray platform (24sure; BlueGnome). The times
for labeling and hybridization were 16 hours and 3 hours,
respectively. The resolution of the microarray was esti-
mated at 2e5 Mbp depending on the specific type and
location of a genetic aberration. The hybridized 24sure
slides were then washed to remove unhybridized DNA with
Hybex Microarray Incubation System (BlueGnome). Micro-
array slides were dried in the vacuum centrifuge and then
scanned. The hybridized fluorophores were excited and the
resulting images of the hybridization read and stored by a
two-channel laser scanner. Finally the results were
analyzed and the whole chromosomal loss or gain reported
with BlueFuse Multi software (BlueGnome).
Thawed ET
When clear results of aCGH were seen, euploid blastocysts
were thawed and transferred with two different protocols
of endometrial preparation. One was natural ovulationcycle that no additional gonadotropin or synthesized
ovarian steroids were given prior to ovulation and the em-
bryos were thawed 6 days after observing serum luteinizing
hormone surge. Another endometrial preparation consisted
of estradiol valerate (Estrade; Synmosa, Taipei, Taiwan)
and 8% intravaginal progesterone gel (Crinone; Merck
Serono, Geneva, Switzerland) supplement and the embryos
were thawed on the sixth day of progesterone administra-
tion.20 Patients with a positive pregnancy test continued
with estrogen and progesterone supplementation until 12
weeks’ gestation.
ETwas performed 3e4 hours after warming, as described
previously.20 One or two embryos were transferred/cycle.
Biochemical pregnancy was confirmed with serum b-human
chorionic gonadotropin test 12 days after ET. Implantation
was determined by the presence of a gestational sac ac-
cording to transvaginal ultrasound at a gestational age of 5
weeks. The ongoing pregnancy was defined as presence of
fetal heart beat until 12 weeks of gestation.
Confirmation of karyotype of fetus with
conventional prenatal diagnosis
In cases where pregnancies were achieved, conventional
prenatal diagnosis with chorionic villi sampling (CVS) or
amniocentesis was offered to confirm the karyotype of the
fetus.
Statistical analyses
Statistical analysis was performed using SPSS version 17.0
software (SPSS Inc., Chicago, IL, USA). Categorical data are
presented as number of events/cases and percentages for
each group of interest. Continuous data are presented as
mean and standard error of the mean.
Results
A total of 12 patients diagnosed with a variety of chromo-
somal translocation, including 11 with reciprocal trans-
location and one with Robertsonian translocation, were
enrolled. The age, karyotype, the reason for karyotyping,
pregnancy history of each couple are listed in Table 1 and
Table 2. The reasons for karyotyping included six cases of
repeated miscarriages, three cases of oligospermia, two
cases of previously affected child, and one case of repeated
IVF failure. The case with repeated IVF failure underwent a
total of eight IVF cycles due to endometriosis factor prior to
karyotyping and all failed. The karyotypes of the spouses
were all normal.
Previous pregnancy history of 12 couples showed a total
of 24 previous pregnancies. These resulted in 20 cases of
spontaneous abortions prior to 12 weeks of gestational age,
one case of intrauterine fetal demise at second trimester,
and one case of elective termination of pregnancy at sec-
ond trimester due to abnormal karyotyping by prenatal
diagnosis. There was one normal live birth, which was
conceived via conventional IVF treatment. The other live
birth was affected with unbalanced autosomal trans-
location, showing congenital hypotonia and developmental
delay.
Table 1 The characteristics of the patients in this cohort.
Case Maternal
age
Paternal
age
Karyotype Reason for karyotyping Previous
miscarriage
Previous
affected
offspring
Previous
IVF/ICSI
cycles prior
to PGD
1 33 33 46XY, t(6;14)(q26;q31) Repeated miscarriage 3 0 0
2 43 45 46XX, t(2;7)(q36.2;p15.1) Affected childa 1 1 0
3 34 36 46XY, t(20;21)(p10;q10) Oligospermia 0 0 0
4 31 35 46XY, t(5;21)(q11.2;q11.2) Repeated miscarriage 2 0 0
5 34 36 46XY, t(9;17)(q34.3;p13.3) Repeated miscarriage 2 0 2
6 35 36 46XY, t(7;10)(q34;q26.12) Affected child 0 2b 0
7 36 35 46XY, t(2;10)(p10;q10) Repeated IVF failure 3 0 8
8 36 42 46XX, t(6;10)(q15;p11.2) Repeated miscarriage 3 0 0
9 32 36 46XY, t(2;14)(p10;p10) Oligospermia 1 0 3
10 35 25 45XY, rob(13;14)(q11;q11) Oligospermia 0 0 0
11 22 25 46XX, t(1;14)(q31;q31) Repeated miscarriage 2 0 0
12 31 32 46XY, t(9;12)(q11;q13) Repeated miscarriage 3 0 0
PGD Z preimplantation genetic diagnosis; rob Z Robertsonian translocation.
a This affected offspring showed limb defects associated with abnormal karyotype inherited paternally and was terminated at 21
weeks of gestation.
b Their first pregnancy resulted in live birth but was affected with unbalanced autosomal translocation, showing congenital hypotonia
and developmental delay. Their second pregnancy also showed unbalanced translocation and they decided to terminate it.
Table 3 Characteristics and outcomes of OPU and PGD
cycles.a
Total number of OPUþPGD cycles 12
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shown in Table 3. A total of 12 PGD cycles were performed
with blastocyst biopsy and aCGH, followed by cryopreser-
vation and thawed ET in the next menstrual cycle. A total of
201 oocytes were retrieved (average 16.8 oocytes/cycle,
range 4e33) and 172 of them were at the metaphase II
stage. Of these, 137 were fertilized normally under intra-
cytoplasmic sperm injection procedure, achieving a 79.7%
fertilization rate. Sixty-one (44.5%) embryos developed into
blastocysts and underwent blastocyst biopsy either on Day 5
(26 embryos, 42.6%) or Day 6 (35 embryos, 57.4%),
depending on the speed of development.
WGA was processed successfully on 55 samples and the
results of aCGH were clearly obtained on all samples with
successful amplification. The smallest detectedTable 2 Characteristics of the patients.
Number of couples 12
Maternal age 33.8  1.2 (25e43)
Paternal age 34.7  1.7 (25e45)
Number of previous miscarriages 1.7  0.4 (0e3)
Number of previous live births 0.2  0.1 (0e1)
Number of IVF/ICSI cycles prior
to PGD
1.2  0.7 (0e8)
Reasons for karyotyping
Oligospermia 3 (25%)
Repeated miscarriage 6 (50%)
Affected child 2 (17%)
Repeated IVF failure 1 (8%)
Values are expressed as mean  standard error of the mean
(range) or n (%).
IVF Z in vitro fertilization; ICSI Z intracytoplasmic sperm in-
jection; PGD Z preimplantation genetic diagnosis.chromosomal aberration is 1.6 Mbp. Among the diagnosed
embryos, 18 of them (32.7%) were unaffected or balanced
without other aneuploidy; 16 (29.1%) were unbalanced
translocation without other aneuploidy; 15 (27.3%) were
unbalanced translocation with other unrelated aneu-
ploidy; and six (10.9%) were unaffected or balanced
translocation but with aneuploidy affecting other unre-
lated chromosomes. Overall, the percentage of abnormal
embryos was 67.3% (37/55) in our cohort. The overallTotal number of oocytes retrieved 201
Mean number of oocytes retrieved 16.8  2.5 (4e33)
Total number of mature oocytes (MII) 172 (85.6%)
Mean number of mature oocytes (MII) 14.3  2.5 (4e31)
Total number of fertilized embryos 137 (79.7%)
Mean number of fertilized embryos 11.4  2.1 (1e23)
Total number of biopsied embryos 61 (44.5%)
Mean number of biopsied embryos 5.1  0.9 (1e11)
Day of biopsy
Day 5 26 (42.6%)
Day 6 35 (57.4%)
Total number of embryos diagnosed 55 (90.2%)
Normal or balanced translocation 18 (32.7%)
Unbalanced, without other aneuploidy 16 (29.1%)
Unbalanced, with other aneuploidy 15 (27.3%)
Balanced, with other aneuploidy 6 (10.9%)
Total number of embryos undiagnosed 6 (9.8%)
MII Z metaphase II; OPU Z oocyte pick-up;
PGD Z preimplantation genetic diagnosis.
a Values are expressed as mean  standard error of the mean
(range) or n (%).
Table 4 Pregnancy outcomes of thawed embryo transfer.
Total number of embryo transfer cycles 10
Total number of embryos thawed 15
Number of embryos surviving after thawing 14 (93.3%)
Total number of embryos transferred 14
Mean number of embryos transferred 1.4  0.2
(1 or 2)
Total number of embryos implanted (sac) 7
Implantation rate/embryo transferred 50% (7/14)
Total number of FHB 7
Pregnancy rate (positive b-hCG)/transfer
cycle
80% (8/10)
Ongoing pregnancy rate/transfer cyclea 60% (6/10)
Ongoing pregnancy rate/PGD cyclea 50% (6/12)
b-hCG Z b-human chorionic gonadotropin; FHB Z fetal heart
beat.
a Ongoing pregnancy was defined as the presence of fetal
heart beat until 12 weeks of gestation.
PGD with aCGH for chromosomal rearrangement 541diagnostic efficacy was 90.2% (55 results from a total of 61
samples) and the main reason for nondiagnosis was
amplification failure.
Thawed ET was performed in nine couples following PGD
cycles as in Table 4. Three couples did not have normal/
balanced embryos. In total 15 normal or balanced embryos
were thawed and 14 survived with a survival rate of 93.3%.
Seven of 14 transferred embryos (50%) implanted, resulting
in three live births and another three ongoing pregnancies.
The mean number of transferred embryos was 1.4. The
ongoing pregnancy rate was 60%/transfer cycle and 50%/
PGD cycle. The prenatal diagnosis with CVS reconfirmed the
results of PGD/aCGH in all six pregnant women. There were
three euploid embryos still cryopreserved for three cou-
ples, which could be transferred in the future. The detailed
karyotypic information of each diagnosed embryo is listed
in Table 5.Discussion
Our study demonstrates an effective strategy of PGD
treatment for the reproductive problems of carriers of
chromosomal translocations using blastocyst biopsy, aCGH,
and thawed ET. Reviewing the literature, we found two
other studies using aCGH to perform PGD for the carriers of
chromosomal translocations.1,3 The diagnostic efficacy
ranged from 90% to 93.5% in our study and the other two
studies, which were comparable with those studies using
FISH.1e3,21,22 However, the clinical pregnancy rate seemed
to be higher in the studies using aCGH, which were 42.9%/
PGD cycle by Fiorentino et al,3 and 50% in our study. The
reported clinical pregnancy rate in those studies using FISH
ranged from 16% to 33%.1e3,9,21e25 More interestingly, no
case of miscarriage took place in our study and the other
two studies using aCGH, whereas the reported miscarriage
rates of the studies using FISH were 2e37.5% in the liter-
ature.1e3,9,21e25 The elevation of clinical pregnancy rate
and elimination of miscarriage in our study and Fiorentino
et al’s study might be due to the advantage of thecomprehensive 24 chromosomal aneuploidy screening pro-
vided by aCGH. More studies will be needed to verify our
preliminary result.
aCGH using 24sure technology was performed for genetic
analysis in our study. It provides 24-chromosome analysis to
screen both the translocation and all the other aneu-
ploidies, instead of a set of usually 5e12 chromosomal
probes used by traditional FISH method. It can detect
spontaneous aneuploidy other than specific translocation
derived from carriers.26,27 In our study, 10.9% (6/55) em-
bryos were normal or balanced at the chromosomes
involved in the translocation but were found to have other
de novo aneuploidies. They will be misdiagnosed as normal
embryos by the conventional FISH method and be trans-
ferred, which might end with poor pregnancy outcomes,
such as miscarriage or an affected offspring.
Array CGH also avoids many technical drawbacks
inherent in the FISH method. One critical but difficult step
is the fixation of a single cell onto a microscopic
slide.13,26,27 Also, the misdiagnosis may happen due to hy-
bridization failure, suboptimal signal interpretation, such
as overlapping signals or split signals.13 Moreover, aCGH
allows automation in data reading through computerized
calculation of signal intensities, instead of interpreting the
signals by eye in the FISH method, which may be subject to
interoperator error.13 Another advantage of aCGH is that it
does not require preclinical validation prior to each IVF
cycle, which is required for FISH. This avoids postponement
of treatment.3,7,28
Both allele dropout (ADO) and preferential amplifica-
tion (PA) can decrease the reliability of PGD, especially
for the autosomal dominant single gene disorder.29
Because amplification failure of the affected allele will
cause serious consequence, one solution is to analyze
more loci near the targeted allele.11,29 From the previous
studies published on single-cell multiple displacement
amplification, the ADO rates and PA rates could reach as
high as 25%.29 If more loci are analyzed at the same time,
ADO rates can be decreased to less than 10% and PA rates
even lower.29 Fiorentino et al also reported that when
three short tandem repeat markers are put in either side
of the translocation breakpoints, the failure rate of the
test is about 0.002%, which happens only when ADO oc-
curs in all markers at the same time.12 For carriers of
chromosomal translocation, the aberrant chromosomal
segments of the unbalanced gametes are much larger,
which usually involve more than four or five continuous
probes on the microarray platform. Therefore the inci-
dence of co-amplification failure of all four or five probes
should also be low.
The smallest aberration detected in our study was a
1.6 Mbp deletion, which is better than FISH or even the
traditional metaphase CGH (5e10 Mbp),1 providing a con-
vincible and satisfactory screening resolution with this
technique. The cost of FISH is US$2167 in our center, no
matter how many embryos are analyzed. The cost of aCGH
depends on the number of analyzed embryos and is US$600/
embryo. The average number of analyzed embryos is 5.1,
giving an average cost of around US$3000 in our study.
Therefore it is often more expensive to perform aCGH than
FISH and both the cost and the benefits should be discussed
with the patients in clinical practice.
Table 5 Detailed information of microarray platform in each diagnosed embryo.
Case Karyotype of the
affected couple
Embryo
no.
Results of microarray platform Final characterization
Chromosomal gain Chromosomal loss
1 46XY, t(6;14)(q26;q31) 1 14q32.12e14q32.33 d Abnormal
2 d 14q32.12e14q32.33 Abnormal
3 Euploid Normal/balanced
4 1q42.2e1q44 Chr. 2 Abnormal
5 No signal Undiagnosed
6 No signal Undiagnosed
7 14q32.12e14q32.33 d Abnormal
8 Euploid Normal/balanced
9 9q21.33e9q34.3;
14q32.12e14q32.33
Chr. 16 Abnormal
10 No signal Undiagnosed
11 d Chr. 14 Abnormal
2 46XX, t(2;7)(q36.2;p15.1) 1 d Chr. 2; 7p22.3e7p15.3 Abnormal
3 46XY, t(20;21)(p10;q10) 1 Euploid Normal/balanced
2 Chr. 1, 3, 5, 9, 13, Y Chr. 4, 8, 18, 21, 22, X Abnormal
3 d 9q31.3e9q34.3; Abnormal
11p15.5e11p15.4;
20p13e20p11.21
4 Euploid Normal/balanced
5 8q23.3e8q24.3;
10q26.2e10q26.3;
11q13.1e11q25;
20p13e20p11.21
d Abnormal
4 46XY, t(5;21)(q11.2;q11.2) 1 21q21.1eq22.3 5q13.2eq35.3 Abnormal
2 Euploid Normal/balanced
3 5p15.33eq13.1 21q11.2eq21.1 Abnormal
4 5q13.2eq35.3;
11p15.5ep15.1
5p15.33eq13.1;
21q21.1eq22.3
Abnormal
5 21q21.1eq22.3 5q13.2eq35.3 Abnormal
6 1p12eq44; 6q22.31eq27;
21q11.2eq22.3
5q13.2eq35.3;
9p24.3e21.3
Abnormal
7 21q11.2eq21.1 5p15.33eq13.1 Abnormal
8 Euploid Normal/balanced
9 22q11.1eq13.31 d Abnormal
10 No signal Undiagnosed
11 5q13.2eq35.3 21q21.1eq22.3 Abnormal
5 46XY, t(9;17)(q34.3;p13.3) 1 9q33.2eq34.3 17p13.3ep12 Abnormal
6 46XY, t(7;10)(q34;q26.12) 1 Euploid Normal/balanced
2 10q26.13eq26.3 Chr. 2, 8; 7q36.1eq36.3 Abnormal
3 Euploid Normal/balanced
4 Euploid Normal/balanced
5 7q36.1eq36.3 Chr. 22; 10q26.13eq26.3 Abnormal
6 Chr. 22; 7q36.1eq36.3 8p23.3ep12;
10q26.13eq26.3
Abnormal
7 46XY, t(2;10)(p10;q10) 1 Chr. 10, 15, 20 Chr. 14, 17, 21 Abnormal
2 10p15.3eq21.1 2p11.12eq37.3 Abnormal
3 Chr. 1, 3, 4, 6, 8, 10, 12,
14, 16, 17, 20, 22
Chr. 2, 5, 7, 9, 11, 13,
15, 18, 19, 21
Abnormal
8 46XX, t(6;10)(q15;p11.2) 1 Euploid Normal/balanced
2 10p15.1ep15.1 6q16.1eq27 Abnormal
3 10p14ep15.3 6q16.1eq27 Abnormal
4 6q21eq27 10p15.3ep13 Abnormal
5 6q21eq27; Chr. 16 10p15.3ep13 Abnormal
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Table 5 (continued )
Case
Karyotype of the
affected couple
Embryo
no.
Results of microarray platform
Final characterizationChromosomal gain Chromosomal loss
9 46XY, t(2;14)(p10;p10) 1 No signal Undiagnosed
2 Euploid Normal/balanced
3 2q36.1eq37.1 10q26.3eq26.3 Abnormal
4 Euploid Normal/balanced
10 45XY, rob(13;14)(q11;q11) 1 1p36.33e1q44;
10p15.3e10q26.3;
12p13.33e15q24.33;
19p13.3e19q13.42
5p15.33e5q35.3;
9p24.3e9q34.3;
21q11.2e21q22.3;
Yp11.31eYq12
Abnormal
2 Euploid Normal/balanced
11 46XX, t(1;14)(q31;q31) 1 Euploid Normal/balanced
2 1p36.33e1q44;
7p22.3e7q36.3
14q11.2e14q24.3 Abnormal
3 Euploid d Normal/balanced
12 46XY, t(9;12)(q11;q13) 1 16p13.3e16q24.3 d Abnormal
2 10p15.3e10q26.3 d Abnormal
3 Euploid Normal/balanced
4 Euploid Normal/balanced
5 e Yp11.2eYq12 Abnormal
6 1p36.33e1q44;
15q11.1e15q26.3;
18p11.32e18q23
d Abnormal
7 d 12p13.33e12q24.33 Abnormal
8 Euploid Normal/balanced
Chr. Z chromosome; rob Z Robertsonian translocation.
PGD with aCGH for chromosomal rearrangement 543The best timing for embryo biopsy is still controversial. It
has been well documented that as many as 66e87% of
cleavage stage embryos exhibit mosaicism,26,30 which
means there are at least two different cell lines in one
embryo. Therefore sampling only one blastomere at an
early developmental stage may not represent the final ge-
netic composition and predict the real destiny of the em-
bryo.26,30 By contrast, sampling several cells (usually 5e10
cells) during blastocyst biopsy can provide more genetic
material for analysis, decreasing the risk of misdiagnosis
due to mosaicism, amplification failure, and allele drop-out
phenomenon.9 It is assumed that performing biopsy on the
trophectoderm, which is extraembryonic and develops into
placental tissue, is less harmful to embryo viability than
Day 3 blastomere biopsy.9,13,14,31 Moreover, it is also highly
cost-effective that only competent embryos capable of
developing to blastocysts and with highest implantation
potential are biopsied.9,18
With the advance of modern laboratory techniques, the
successful rate of blastocyst culture and cryopreservation
has yielded improving and satisfying results.5,31,32 Embryo
cryopreservation and thawed ET has become the new trend
of ARTwith many advantages. First, it can decrease the risk
of ovarian hyperstimulation syndrome.33 Second, because
PGD is usually performed at a limited number of specialized
genetic laboratories, thawed ET provided ample time to
transport the biopsied samples from the remote infertility
clinic and to perform genetic diagnosis.7 Third, it has been
shown that the endocrionological status and the uterine
receptivity are altered by ovarian stimulation. That maydecrease the implantation potential in a fresh transfer
cycle, especially in a high responder.34e36 ET in a subsequent
thawed cycle can provide a more natural and synchronized
endometrial environment for embryonic implantation.13,31
Our data also showed a high implantation rate of 50%.
In summary, for carriers with chromosomal trans-
locations, our study describes an feasible PGD strategy,
applying blastocyst biopsy, aCGH, embryo cryopreserva-
tion, and thawed ET. aCGH can provide comprehensive 24-
chromosome analysis and the ongoing pregnancy rate was
50%/PGD cycle in our study, which seems to be higher than
previous studies using FISH methods. There was no case of
miscarriage. Although the number of the patients in our
study is too small to draw robust conclusions, the pre-
liminary results may support a promising choice of future
PGD treatment for these patients.Acknowledgments
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